Search: onr:"swepub:oai:lup.lub.lu.se:1e5361d1-2eb0-493e-b321-ce9c2ab5dfbf" >
Effectiveness and i...
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma : Real-world evidence from Sweden
-
- Uttervall, Katarina (author)
- Karolinska Institutet,Karolinska Institute,Karolinska Inst, Sweden; Karolinska Inst, Sweden
-
- Tätting, Love (author)
- Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US
-
- Lemonakis, Konstantinos (author)
- Lund University,Lunds universitet,Myelomgruppen,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Myeloma research group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Sweden
-
show more...
-
- Majd, Mousa (author)
- Karolinska Institute,Karolinska Inst, Sweden
-
- Crafoord, Jacob (author)
- Örebro University Hospital,Orebro Univ Hosp, Sweden
-
- Olsson, Mikael (author)
- Hallands Sjukhus Varberg, Sweden
-
- Mellqvist, Ulf Henrik (author)
- Sahlgrenska University Hospital,Sahlgrens Univ Hosp, Sweden
-
- Hansson, Markus (author)
- Sahlgrenska University Hospital,Sahlgrens Univ Hosp, Sweden
-
- Nahi, Hareth (author)
- Karolinska Institutet,Linköpings universitet,Linköping University,Karolinska Institute,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US,Karolinska Inst, Sweden
-
show less...
-
(creator_code:org_t)
- WILEY, 2024
- 2024
- English.
-
In: Cancer Medicine. - : WILEY. - 2045-7634. ; 13:8
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T-cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections. Methods/Results: This study evaluated the efficacy and safety of BCMA T-cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression-free survival at 15 months. Conclusions: Despite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real-world data highlight the potential of BCMA T-cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- bispecific antibodies
- immunotherapy
- multiple myeloma
- real-world data
- bispecific antibodies; immunotherapy; multiple myeloma; real-world data
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database